Blood Coagulants Companies

Latest MEA Blood Coagulants Companies Update

• 
  Nov 2023: As both pharmaceutical companies struggle to meet demand, Novo Nordisk and Eli Lilly announced phenomenal sales from the current crop of diabetic and weight-loss medications they have pioneered. Novo, a Danish company, recorded $8.4 billion in revenue during the last three months, up 29% over the same period last year. More than half of sales were attributed to the company's popular medications, Wegovy and Ozempic. Lilly, an Indianapolis-based company, reported $9.5 billion in revenue for the most recent quarter—a 37 percent rise—driven primarily by Mounjaro's rapidly expanding sales. In the weight-loss medicine craze that has enthralled consumers and captured Wall Street's attention, the two businesses have emerged as the leading forces. With the aid of a new production plant in North Carolina that opened this year, Lilly has increased the supply of Mounjaro, and the FDA's drug shortage database lists all of the medication's strengths as available. Despite having differing chemical compositions, Mounjaro and Ozempic both slow the emptying of the stomach and assist control blood sugar.

• Pfizer Inc. (U.S.)


• Bayer AG (Germany)


• Novo Nordisk AS (Dernmark)


• Shire (Republic of Ireland)


• SOBI (Sweden)


• Octapharma (Switzerland)


• CSL Limited (Australia)